Skip to main content
. 2012 Feb 27;119(21):5030–5036. doi: 10.1182/blood-2011-11-389304

Table 3.

Variables from a multivariate analysis describing the probability of developing severe aGVHD

Variable No. RR 95% CI P
Diagnosis 57
    Non-CML 1
    CML 2.54 1.06-6.04 .036
CD8+ T-cell dose 57
    < 47.7 × 106 1
    > 47.7 × 106 1.7 0.75-3.86 .2
Total iNKT-cell dose 57
    > 0.057 × 106 1
    < 0.057 × 106 1.36 0.58-3.18 .48
CD4+ iNKT-cell dose 57
    > 0.026 × 106 1
    < 0.026 × 106 5.51 0.87-35.1 .07
CD4− iNKT-cell dose 57
    > 0.031 × 106 1
    < 0.031 × 106 4.27 1.68-10.85 .0023

“Best” model from a backward-stepping procedure that included the variables found significant at the P < .1 level in univariate analyses: CML diagnosis, CD8+ T-cell dose, total iNKT-cell dose, CD4+ iNKT-cell dose, and CD4− iNKT-cell dose.